About Sangon Biotech
Sangon Biotech is a company based in Shanghai (China) founded in 2003. Sangon Biotech has raised $300 million across 2 funding rounds from investors including CITIC Capital, Qiming Venture Partners and Greenwoods Investments. Sangon Biotech operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$300 M (USD)
in 2 rounds
-
Latest Funding Round
$290 M (USD), Series B
Apr 20, 2023
-
Investors
CITIC Capital
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sangon Biotech
Sangon Biotech has successfully raised a total of $300M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $290 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sangon Biotech
Sangon Biotech has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include CITIC Capital, Qiming Venture Partners and Greenwoods Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Acquisitions are targeted by CPE as a private equity firm.
|
Locked | Locked | Locked | |
|
Private equity investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Sangon Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sangon Biotech
Investment portfolio details for Sangon Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sangon Biotech
Detailed financials for Sangon Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sangon Biotech Comparisons
Peer comparison for Sangon Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sangon Biotech
Sangon Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and Miltenyi Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
Detailed competitors of Sangon Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sangon Biotech
Complete news archive for Sangon Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sangon Biotech
Sangon Biotech was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Sangon Biotech is headquartered in Shanghai, China.
Sangon Biotech is a funded company, having raised a total of $300M across 2 funding rounds to date.
Sangon Biotech was founded in 2003 and is based in Shanghai, China. Operations focus on the biotechnology sector, where services such as oligonucleotide, gene, and peptide synthesis are delivered. DNA and next-generation sequencing, along with protein, antibody, and molecular biology services, are also offered. Reagents including PCR and enzymes, plus ELISA and PCR kits, are supplied to support research activities.
Sangon Biotech's top competitors include Abcam, Sino Biological and Meridian Bioscience.
Sangon Biotech has 8 investors. Key investors include CITIC Capital, Qiming Venture Partners, Greenwoods Investments, CPE, and GL Capital.